Ebos Group (EBO.NZ) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $2.60B | Exchange | NZE |
| Sector | Healthcare | Industry | Medical - Distribution |
| Country | AU | CEO | Adam Luke Hall |
| IPO Date | 1986-06-16 | CAGR | 22.78% |
| Employees | 5,533 | Website | www.ebosgroup.com |
| Div. Yield | 5.5% | Payout Ratio | 26% |
| Buy Back Yield | — | Total Yield | 5.5% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $4.61B | P/E | 17.32 | Forward P/E | 17.53 | PEG | 2.63 |
| P/S | 0.26 | P/B | 1.41 | P/CF | 52.62 | P/FCF | 54.14 |
| Sales | $16.17B | Sales 1Y | 4.45% | Sales 3Y | 68.61% | Sales 5Y | 113.25% |
| EPS | $0.73 | EPS 1Y | -9.79% | EPS 3Y | 24.04% | EPS 5Y | 72% |
| Sales QoQ | -23.14% | EPS QoQ | 25.93% | Sales QoQ Avg | 30.82% | EPS QoQ Avg | -2.12% |
| Gross Margin | 10.29% | Operating Margin | 2.45% | Profit Margin | 1.43% | ROCE | 7.58% |
| ROA | 3% | ROE | 8% | Altman Z Score | 4.21 | Piotroski Score | 4 |
| Current Ratio | 1.24 | Quick Ratio | 0.74 | Cash Ratio | 0.09 | Op. CF Ratio | 0.02 |
| Debt/Equity | 0.82 | Debt/Assets | 0.3 | Lt Debt/Equity | 0.78 | Lt Debt/Cap. | 0.39 |
| Intrst Cov. | 3.25 | Inventory Turnover | 7.95 | Asset Turnover | 1.99 | Receivables Turnover | 8.88 |
| Enterprise Value | $4.61B | P/E Ratio | 17.32 |
| Forward P/E | 17.53 | PEG Ratio | 2.63 |
| P/S Ratio | 0.26 | P/B Ratio | 1.41 |
| P/CF Ratio | 52.62 | P/FCF Ratio | 54.14 |
| EPS | $0.73 | EPS Growth 1Y | -9.79% |
| EPS Growth 3Y | 24.04% | EPS Growth 5Y | 72% |
| Revenue Growth 1Y | 4.45% | Gross Margin | 0.1% |
| Operating Margin | 0.02% | Profit Margin | 0.01% |
| ROE | 0.08% | ROA | 0.03% |
| ROCE | 0.08% | Current Ratio | 1.24 |
| Quick Ratio | 0.74 | Cash Ratio | 0.09 |
| Debt/Equity | 0.82 | Interest Coverage | 3.25 |
| Altman Z Score | 4.21 | Piotroski Score | 4 |
Ebos Group (EBO.NZ) valuation & financials
Ebos Group (EBO.NZ) has a market capitalization of 2.60B NZD and trades at a price-to-earnings ratio of 17.3. It operates in the Healthcare sector (Medical - Distribution).
Ebos Group's revenue grew +4.4% over the last year.
Ebos Group's next earnings report is scheduled for August 25, 2026; analysts estimate EPS of 0.42 NZD.
Ebos Group (EBO.NZ) — frequently asked questions
When does Ebos Group (EBO.NZ) report earnings next?
Ebos Group is expected to report earnings on August 25, 2026. Analysts estimate EPS of 0.42 NZD.
What is Ebos Group's market cap?
Ebos Group (EBO.NZ) has a market capitalization of 2.60B NZD.
What is EBO.NZ's P/E ratio?
Ebos Group trades at a price-to-earnings ratio of 17.3, with trailing twelve-month EPS of 0.73 NZD.
How fast is Ebos Group growing?
Ebos Group's revenue grew +4.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)